ImmuPharma (LON:IMM) Stock Price Up 27.3% - Here's Why

Key Points

• ImmuPharma's stock price surged 27.3% to GBX 12.60 ($0.17) during trading, with a notable 46% decline in share volume compared to its average session.
• The company has a market capitalization of £63.34 million and a significant P/E ratio of -1,415.73, indicating it is currently unprofitable.
• ImmuPharma is a specialty biopharmaceutical company focused on developing peptide-based therapeutics, including its lead candidate, P140 (Lupuzor™), for autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report) shot up 27.3% during trading on Saturday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares were traded during trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Performance

The firm has a market capitalization of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53. The firm's 50 day simple moving average is GBX 7.92 and its 200 day simple moving average is GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.